不同剂量阿立哌唑对奥氮平治疗精神分裂症患者稳态血药浓度的影响  

Effects of Different Doses of Aripiprazole on Steady-state Plasma Con⁃centrations of Olanzapine in Patients with Schizophrenia

作　　者：孟莉 MENG Li(Department of Psychiatry,Xuzhou Civil Affairs Psychiatric Hospital,Xuzhou,Jiangsu Province,221400 China)

机构地区：[1]徐州市民政精神病医院精神科,江苏徐州221400

出　　处：《中外医疗》2022年第18期105-108,共4页China & Foreign Medical Treatment

摘　　要：目的分析精神分裂症奥氮平治疗中不同剂量阿立哌唑对其稳态血药浓度影响。方法随机选取2019年6月—2021年6月该院的80例精神分裂症患者为研究对象,以阿立哌唑剂量不同分两组,各40例,小剂量组用药剂量5 mg/d,大剂量组用药剂量15 mg/d,对比两组治疗前、治疗后2周、12周奥氮平血药浓度、体质指数、代谢参数、临床疗效总评量表总分(CGI)阳性与阴性症状量表总分(PANSS)。结果治疗前两组血药浓度差异无统计学意义(P>0.05);大剂量组治疗2周、12周后奥氮平血药浓度为(38.05±7.85)、(40.15±5.75)ng/mL明显高于小剂量组,差异有统计学意义(t=3.957、6.555,P<0.05)。两组治疗前体质指数对比差异无统计学意义(P>0.05),治疗2周、12周后大剂量组为(22.10±1.48)kg/m^(2)、(23.45±2.15)kg/m^(2),与小剂量组对比差异无统计学意义(t=0.153、0.480,P>0.05)。两组治疗前后代谢指数对比差异无统计学意义(P>0.05)。治疗前两组CGI总分、PANSS总分差异对比差异无统计学意义(P>0.05),治疗2周、12周后,大剂量组CGI总分为(2.50±1.06)分、(2.18±0.89)分,PANSS总分为(47.85±9.70)分、(45.23±8.40)分,与小剂量比较差异无统计学意义(t=0.085、0.094、0.139、0.016,P>0.05)。结论精神分裂症奥氮平治疗时予以不同剂量阿立哌唑会影响稳态血药浓度和代谢,但对患者的体质指数、代谢指数和CGI、PANSS评分影响不大。Objective To analyze the effect of different doses of aripiprazole on the steady-state plasma concentra‐tion of olanzapine in the treatment of schizophrenia.Methods A total of 80 patients with schizophrenia in the hospital from June 2019 to June 2021 were randomly selected as the research objects.According to different doses of aripipra‐zole,they were divided into two groups,40 cases in each group.The low-dose group was administered at a dose of 5 mg/d,and the high-dose group was administered at a dose of 15 mg/d,the olanzapine blood concentration,body mass index,metabolic parameters,total score of clinical efficacy total score(CGI)and total score of negative symptom scale(PANSS)were compared between the two groups before treatment,2 weeks and 12 weeks after treatment.Re⁃sults There was no statistically significant difference in blood drug concentration between the two groups before treat‐ment(P>0.05).The plasma concentrations of olanzapine(38.05±7.85)ng/mL and(40.15±5.75)ng/mL in the highdose group were significantly higher than those in the low-dose group after 2 weeks and 12 weeks of treatment(t=3.957,6.555,P<0.05).There was no statistically significant difference in body mass index between the two groups before treatment(P>0.05).After 2 and 12 weeks of treatment,the high-dose group was(22.10±1.48)kg/m^(2) and(23.45±2.15)kg/m^(2).Compared with the low-dose group,there was no statistically significant difference(t=0.153,0.480,P>0.05).There was no statistically significant difference in the metabolic index between the two groups before and after treatment(P>0.05).Before treatment,there was no statistically significant difference in CGI total score and PANSS total score between the two groups(P>0.05).After 2 weeks and 12 weeks of treatment,the total CGI scores in the high-dose group were(2.50±1.06)points,(2.18±0.89)points,and the PANSS total scores were(47.85±9.70)points and(45.23±8.40)points.Compared with the low-dose group,there was no statistically significant difference(t=0.085,0.094,0.139,0.0

关 键 词：精神分裂症 奥氮平 阿立哌唑 不同剂量 

分 类 号：R749[医药卫生—神经病学与精神病学]